Abstract:Concomitant inhibition of key epigenetic pathways involved in silencing tumor suppressor genes has been recognized as a promising strategy for cancer therapy. Herein, we report a first-in-class series of quinoline-based analogues that simultaneously inhibit histone deacetylases (from a low nanomolar range) and DNA methyltransferase-1 (from a mid-nanomolar range, IC50 < 200 nM). Additionally, lysine methyltransferase G9a inhibitory activity is achieved (from a low nanomolar range) by introduction of a key lysine mimic group at the 7-position of the quinoline ring. The corresponding epigenetic functional cellular responses are observed: histone-3 acetylation, DNA hypomethylation, and decreased histone-3 methylation at lysine-9. These chemical probes, multitarget epigenetic inhibitors, were validated against the multiple myeloma cell line MM1.S, demonstrating promising in vitro activity of 12a (CM-444) with GI50 of 32 nM, an adequate therapeutic window (>1 log unit), and a suitable pharmacokinetic profile. In vivo, 12a achieved significant antitumor efficacy in a xenograft mouse model of human multiple myeloma.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02255?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02255</a>.Protocols for preparative HPLC purification methods; method for high-resolution mass spectrometry (HRMS) of the final compounds; methods for analytical HPLC and UHPLC; HPLC or UHPLC traces of the final compounds; NMR spectra (1H & 13C) of the final compounds; biochemical profiling of 9a and 12aversus DNMT and HDAC isoforms; H3K9me2 and H3Ac marks after treatment with A-366, Panobinostat, and Decitabine in MM1.S cells; hypomethylating activity of compounds 9a and 12a in JJN3 cells; body weight of mice treated with compound 12a; and plasmatic concentrations of 12a after administration (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02255/suppl_file/jm0c02255_si_001.pdf">PDF</a>)Molecular formula strings together with their IC50 values (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02255/suppl_file/jm0c02255_si_002.csv">CSV</a>)Results from docking studies reported in Figure 2:G9a compound 9a complex (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02255/suppl_file/jm0c02255_si_003.pdb">PDB</a>)DNMT1 compound 9a complex (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02255/suppl_file/jm0c02255_si_004.pdb">PDB</a>)HDAC1 compound 9a complex (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02255/suppl_file/jm0c02255_si_005.pdb">PDB</a>)HDAC6 compound 9a complex (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02255/suppl_file/jm0c02255_si_006.pdb">PDB</a>)This article has not yet been cited by other publications.

5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma

Design, synthesis and biological evaluation of novel (E)-N-phenyl-4-(pyridine-acylhydrazone) benzamide derivatives as potential antitumor agents for the treatment of multiple myeloma (MM)

Identification of a Novel C-Myc Inhibitor 7594-0037 by Structure-Based Virtual Screening and Investigation of Its Anti-Cancer Effect on Multiple Myeloma

A novel phosphoramide compound, DCZ0805, shows potent anti-myeloma activity via the NF-κB pathway

4-Chlorbenzoyl Berbamine, a Novel Derivative of the Natural Product Berbamine, Potently Inhibits the Growth of Human Myeloma Cells by Modulating the NF-κB and JNK Signalling Pathways

The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13–MAPK–YWHAE signaling pathway

Extended Fuzzy C-Means and Genetic Algorithms to Optimize Power Flow Management in Hybrid Electric Vehicles

Preclinical Activity Of Dcz3301, A Novel Aryl-Guanidino Compound In The Therapy Of Multiple Myeloma

A Novel Sulfonamide Agent, MPSP-001, Exhibits Potent Activity Against Human Cancer Cells in Vitro Through Disruption of Microtubule

Novel Dual-Targeting C-Myc Inhibitor D347-2761 Represses Myeloma Growth Via Blocking C-Myc/max Heterodimerization and Disturbing Its Stability

Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with In Vivo Efficacy in Multiple Myeloma

Berbamine, a Novel Nuclear Factor Κb Inhibitor, Inhibits Growth and Induces Apoptosis in Human Myeloma Cells

Discovery of potent small molecule inhibitors of histone lysine methyltransferase NSDs

Design, synthesis and biological evaluation of sulfonamides inhibitors of XPO1 displaying activity against multiple myeloma cells

A novel 2-iminobenzimidazole compound, XYA1353, displays in vitro and in vivo anti-myeloma activity via targeting NF-κB signaling

Covalent inhibition of NSD1 histone methyltransferase

Discovery of CZL-046 with an ( S )-3-Fluoropyrrolidin-2-one Scaffold as a p300 Bromodomain Inhibitor for the Treatment of Multiple Myeloma

A novel phosphoramide compound, DCZ0847, displays in vitro and in vivo anti-myeloma activity, alone or in combination with bortezomib

A Novel Small Molecule Agent Displays Potent Anti-Myeloma Activity by Inhibiting the JAK2-STAT3 Signaling Pathway.

Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.

Cost of 3-dimensional imaging-based surgery.